For the first quarter of 2026, analysts anticipate Pfizer will report a consensus revenue of $13.82 billion and adjusted EPS of $0.74, while the stock currently trades at $26.33, well below the average price target of $29.17.
Investors are primarily focused on the performance of the oncology segment and the integration of Seagen to gauge if new products can successfully offset the continued decline in COVID-19 related sales.
The company is navigating a transition year marked by patent expirations and a projected $1.5 billion headwind from loss of exclusivity impacts. Management's ability to maintain its full-year guidance and achieve projected cost savings of $7.2 billion remains a critical indicator of the turnaround's success.